A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Biomarker; Therapeutic Use
- Acronyms START 2
- 05 Jun 2018 Primary endpoint (Relapse-free survival rate (3-years recurrence free survival rate)) has been met, according presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.